New strategies in ewing sarcoma: Lost in translation?

Fernanda I. Arnaldez, Lee J. Helman

Research output: Contribution to journalArticlepeer-review


Ewing sarcoma is the second most common pediatric malignant bone tumor. Aggressive multimodality therapy has led to an improvement in outcomes, particularly in patients with localized disease. However, therapy-related toxicities are not trivial, and the prognosis for patients with relapsed and/or metastatic disease continues to be poor. In this article, we outline some of the promising therapies that have the potential to change the Ewing sarcoma therapeutic paradigm in the not-too-distant future: insulin-like growth factor receptor inhibitors, targeting of the fusion protein, epigenetic manipulation, PARP inhibitors, and immunotherapy.

Original languageEnglish (US)
Pages (from-to)3050-3056
Number of pages7
JournalClinical Cancer Research
Issue number12
StatePublished - Jun 15 2014
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'New strategies in ewing sarcoma: Lost in translation?'. Together they form a unique fingerprint.

Cite this